News
ADAG
3.570
-0.28%
-0.010
Weekly Report: what happened at ADAG last week (0601-0605)?
Weekly Report · 5d ago
Weekly Report: what happened at ADAG last week (0525-0529)?
Weekly Report · 06/01 10:17
Weekly Report: what happened at ADAG last week (0518-0522)?
Weekly Report · 05/25 10:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 05/21 21:06
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
NASDAQ · 05/19 21:07
Weekly Report: what happened at ADAG last week (0511-0515)?
Weekly Report · 05/18 10:20
Weekly Report: what happened at ADAG last week (0504-0508)?
Weekly Report · 05/11 10:18
Weekly Report: what happened at ADAG last week (0427-0501)?
Weekly Report · 05/04 10:15
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)
TipRanks · 05/02 17:20
Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints
TipRanks · 04/27 10:55
Weekly Report: what happened at ADAG last week (0420-0424)?
Weekly Report · 04/27 10:18
Weekly Report: what happened at ADAG last week (0413-0417)?
Weekly Report · 04/20 10:14
Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers
TipRanks · 04/17 20:53
Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR
TipRanks · 04/17 20:15
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Benzinga · 04/17 20:03
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Barchart · 04/17 15:01
Adagene Looks Attractive With ADG126 And Validating Partnerships
Seeking Alpha · 04/16 18:08
Weekly Report: what happened at ADAG last week (0406-0410)?
Weekly Report · 04/13 10:18
Adagene Inc. - Depositary Receipt (ADAG) Price Target Increased by 11.46% to 11.57
NASDAQ · 04/09 03:43
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/08 17:05
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.